Denis Chem Lab share price, P/E, ROE & financials

On 6 Nov 2026, Denis Chem Lab was priced at ₹57.83, or 10.1× trailing earnings, against an industry P/E of 28.7×, and the shares are 38% below their 52-week high. Its ROCE of 13% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers, and sales and net profit grew 4.2% and 2.3% a year over 3 years. Its dividend yield is 4.3%. It is a small-cap company with a market cap of ₹80 Cr, ranked 124th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 38% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹55.70
Day high: ₹58.20
Day low: ₹55.70
Prev. close: ₹56.73
Volume: 7K

Health check

1 good · 2 fair · 3 to check

ReturnsBehind
−38.2% over a year, better than 0 of 7 peers.
Price tagCheaper
P/E 10.1 vs industry 28.7.
GrowthSlow
Sales +4.2%, profit +2.3% a year over 3 years.
ProfitabilityAverage
ROCE 13.3% vs peer median 17.9%.
Balance sheetFair
Piotroski 5 of 9.
Red flags2 to check
Quarterly profit down 17.4% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹80 Cr, #124 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹182 Cr · profit ₹8 Cr

Market cap: ₹80 Cr; Small cap
P/E: 10.1; Industry 28.7
Price to book: n/a; Peers 4.99
Dividend yield: 4.32%
ROE: 9.5%; Peers 14.7%
ROCE: 13.3%; Peers 17.9%
Debt to equity: n/a
EPS (TTM): ₹5.75
OPM (TTM): 9.1%; Net margin 0.0%
Sales growth: +1.7%; Latest quarter vs a year ago
Profit growth: −17.4%; Latest quarter vs a year ago
Price to sales: 0.44

Strengths

Dividend yield of 4.32%.
P/E of 10.1 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

Risks to check

Quarterly profit down 17.4% on a year ago.
38% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Denis Chem Lab

Denis Chem Lab Limited, a pharmaceutical company, engages in the manufacturing and marketing of sterile intravenous injectable products for human and veterinary use in India. The company's products include antibiotic injections, diuretic injections, parenteral amino acid injections, plasma volume expanders, anti-anaerobic injections, anti-pyretic injections, irrigation and dialysis solutions, etc. It also provides contract manufacturing services for third…

Headquarters: Ahmedabad
Sector: Healthcare
ISIN: INE051G01012
Website: denischemlab.com

Price range

52 weeks

₹54.50₹92.80

Today

₹55.70₹58.20

Avg volume (3M): 20.2K
1-year return: minus 38.2%
From 52-week high: minus 37.7%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
DENISCHEMDenis Chem Lab	57.83	plus 1.94%	80	10.1	–	13.3%	9.5%	9.1%	4.2%	2.3%	4.32%	minus 38.2%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
43.3	46.2	45.5	46.8	44
38.5	41.9	39.5	44.2	40.2
4.8	4.3	6	2.5	3.8
11.1%	9.2%	13.2%	5.4%	8.7%
0.3	0.6	0.4	0.5	0.5
0.2	0.2	0.2	0.2	0.1
1.6	1.7	1.8	1.7	1.5
3.3	3	4.4	1.1	2.6
25.3%	26.9%	24.7%	64.9%	22.6%
2.5	2.2	3.3	0.4	2
1.78	1.60	2.39	0.29	1.47

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +4.2%
Profit CAGR 3Y: +2.3%
EPS CAGR 3Y: +2.3%
ROE: 9.5%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
161	168	173	182
–	+4.4%	+3.3%	+4.9%
140	146	156	163
21	22.1	17.6	19
13.0%	13.2%	10.2%	10.5%
0.1	1.1	1.4	1.5
0.3	0.3	0.1	0.5
7.8	6.9	6.9	6.8
−2.1	−0.8	−1	−1.3
10.9	15.1	11.1	11.9
28.0%	26.3%	27.3%	29.3%
7.9	11.2	8.1	8.4
–	+41.9%	minus 27.6%	+4.1%
5.66	8.04	5.82	6.06

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
13.9	13.9	13.9	13.9
58.4	66.5	71.2	77.7
1.9	1	0.8	4.2
25.3	27.9	26.3	29.1
99.4	109	112	125
38.3	38.3	39.2	37
3.1	0.9	0.5	–
1.5	1.3	2.2	2.1
16.9	24.6	25.9	28.6
39.6	44.2	44.6	57.1
99.4	109	112	125

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
16.3	17.8	12.1	4.1
−11.2	−14.9	−8.2	−5
−4	−4.2	−4.2	0.4
1.2	−1.3	−0.3	−0.4
−4.7	−6.9	−7.6	−4.7
11.6	10.9	4.5	−0.5
−2.1	−2.8	−3.5	−2.1

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you